WaveMan
WaveMan · Company
MLAB · Mesa Laboratories Inc /Co/
> Search tickers & screens ⌘K
LIVE
← All companies

MLAB Mesa Laboratories (MLAB) Insider Trading, Ownership & Congress Trades

Industrials · Industrial instruments for measurement, display, and control · CIK 0000724004
Quote by TradingView
C-suite buying · 1Form 144 · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
15
Codes C/M, not in net · $1.3M priced

What the filings say about MLAB

Insiders, 180 days
-$667.8K net sold
2 buyers · 4 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$5.1M
2 notices

Mesa Laboratories insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, MESA LABORATORIES INC /CO/ insiders sold a net $667.8K of stock across 73 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Tripeny R Tony
Director
BUY
2026-08-17 SECtraded 2026-08-13
900
$102.3K
+20.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 10, 2026.
  • +16.1% median (+16.1% mean) 90-day return after 2 previous buys.
  • The trade is 14.3% of the 6,298 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: Director Tripeny R Tony bought about $102.3K of MLAB on Aug 13, 2026; 1 other insider bought within 30 days.
Kadia Siddhartha
President and CEO
BUY
2026-08-17 SECtraded 2026-08-13
7,093
$800.1K
+20.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 7,093 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: President and CEO Kadia Siddhartha bought about $800.1K of MLAB on Aug 13, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
Sullivan John James
Director
SELL
2026-08-17 SECtraded 2026-08-13
7,093
$800.1K
+20.5%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Jun 7, 2022.
  • The trade is 39.8% of the 17,834 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Director Sullivan John James sold about $800.1K of MLAB on Aug 13, 2026, the largest insider sale at the company since 2025.
Crennen Lyndsey Elizabeth
CAO
SELL
2026-06-23 SECtraded 2026-06-22
442
$39.6K
+37.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 16, 2026.
  • The trade is 21.9% of the 2,020 shares held after it.
  • 2 other insiders sold within 30 days.
Insider activity: CAO Crennen Lyndsey Elizabeth sold about $39.6K of MLAB on Jun 22, 2026; 2 other insiders sold within 30 days.
Archbold Brian David
SVP Operations
SELL
2026-06-23 SECtraded 2026-06-22
2,516
$225.2K
+37.5%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jun 16, 2026.
  • The trade is 39.5% of the 6,377 shares held after it.
  • 2 other insiders sold within 30 days.
Insider activity: SVP Operations Archbold Brian David sold about $225.2K of MLAB on Jun 22, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days.
73 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 68 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$667.8K over 180 days
+$102.3K over 90 days
more than 60% of Industrials
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+3.4% year over year
below 57% of Industrials
Margin
2.7% net margin
below 61% of Industrials
Buybacks
no share repurchases reported
Short interest
9.0% of the float short (float per yahoo 2026-10-26) · 3.7 days to cover · settled 2026-09-30
more than 87% of Industrials
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MLAB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+65.9%12M
-10%+20%+51%+82%2025-102025-122026-022026-042026-062026-082026-10 2026-08-13 · Kadia Siddhartha bought $800.1K2026-08-13 · Sullivan John James sold $800.1K2026-06-22 · Sakys John sold $253.0K2026-03-10 · Ladiwala Shiraz Shabanali bought $252.8K2026-06-22 · Archbold Brian David sold $225.2K2026-06-16 · Sakys John sold $123.9K2026-06-16 · Archbold Brian David sold $116.6K2026-08-13 · Tripeny R Tony bought $102.3K2026-03-10 · Tripeny R Tony bought $99.9K2026-03-10 · Capone Mark Christopher bought $99.3K2026-06-22 · Crennen Lyndsey Elizabeth sold $39.6K2026-06-16 · Crennen Lyndsey Elizabeth sold $11.9K2026-08-27 · Owens Gary M filed to sell $2.6M2026-08-21 · Owens Gary M filed to sell $2.5M2026-06-22 · Archbold Brian David filed to sell $225.2K2026-06-22 · Sakys John filed to sell $253.0K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MLAB: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in MLAB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MLAB planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Owens Gary M
Filed 2026-08-27
$2.6M
Owens Gary M
Filed 2026-08-21
$2.5M
Archbold Brian David
Filed 2026-06-22
$225.2K
Sakys John
Filed 2026-06-22
$253.0K
Executive pay vs shareholder return · Gary Owens
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.6M
$516.2K
$2.3M
-63%
-65%
2024
$6.6M
$7.9M
$2.3M
-50%
-67%
2023
$5.4M
$78.0K
$1.8M
-54%
-57%
2022
$5.2M
-$3.6M
$1.5M
-28%
-54%
2021
$18.1M
$16.8M
$1.5M
+5%
-34%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $667.8K sold by insiders over 180 days, $5.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
AXONTMOROKPKOHOFLXXPELSYMLIIITRIWABSNASXI

MLAB financials

Revenue growth
+3.4%
XBRL, annual
Net margin
2.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$249.7M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+1.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$52.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.35x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Cash flow to debt
0.84x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Return on equity
+2.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+1.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+5.2%
operating income after a 48.7% effective tax rate, over LongTermDebt as filed 2026-06-30 (includes the current portion) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+6.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
152.79x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$762.1M
market value at close 2026-10-26 on 2026-08-03 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
FCF yield
+7.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-032025-032024-032023-03
Revenue$249.1M$241.0M$216.2M$219.1M
Gross profit$158.3M$150.9M$133.2M$133.7M
Operating income$18.5M$16.3M-$272.1M$3.3M
Net income$6.7M-$2.0M-$254.2M$930.0K
EPS (diluted)1.21-0.36-47.200.17
Operating cash flow$42.8M$46.8M$44.1M$28.0M
Cash$26.9M$27.3M$28.2M$32.9M
Long-term debt$67.5M$71.2M$171.2M$170.3M
Dividends paid$3.5M$3.5M$3.4M$3.4M
SEC XBRL, fiscal years, as known on 2026-10-28

MLAB Stock Sonar score 5/7 axes

Find similar shapesCompare

MLAB ranks highest on financial health (72nd percentile) and insider conviction (72nd), and lowest on profitability (33rd), among Industrials peers.

ProfitHealthGrowthInsidersRisk
Profitability
33
Inputs
  • Return on equity+2.7% · 32 pct, sector of 198
  • Return on assets+1.1% · 39 pct, sector of 224
  • Return on invested capital+5.2% · 15 pct, sector of 107
  • Return on capital employed+6.9% · 47 pct, sector of 195
Financial health
72
Inputs
  • Debt to equity0.35x · 55 pct, sector of 214
  • Cash flow to debt0.84x · 88 pct, sector of 173
Growth
43
Inputs
  • Revenue growth, YoY+3.4% · 43 pct, sector of 254
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
72
Inputs
  • Net Form 4 buying (codes P and S), 180d-$668K · 58 pct, sector of 170
  • Insider buyers, 180d2 · 86 pct, sector of 172
Risk and compliance
40
Inputs
  • Short interest, % of float+9.0% · 18 pct, sector of 269
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5y0.00 per $1B · 100 pct, sector of 191
  • New text in Risk Factors, latest 10-K+60.0% · 2 pct, sector of 197
2 not measured: Institutional and government, US patents
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MLAB filings, in plain words

Are Mesa Laboratories insiders buying or selling MLAB?

In the 180 days to 2026-10-28, Mesa Laboratories insiders were net sellers, a net $667.8K: $902.4K of purchases and $1.6M of sales reported on Form 4, by 2 buyers and 4 sellers.

Are there planned insider sales of MLAB?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $5.1M of stock; the latest, by Owens Gary M, was filed 2026-08-27.

Read the full summary

In the 180 days to 2026-10-28, Mesa Laboratories insiders were net sellers of MLAB, a net $667.8K across purchases and sales reported on Form 4 by 2 buyers and 4 sellers. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $5.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies